Clinical Trial Update: A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients [Phase 1]

View source ↗

Summary

This is a Phase 1 trial update studying oral OP-1250 in combination with palbociclib for hormone receptor-positive, HER2-negative breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• OP-1250 (OP-1250)
• Palbociclib (palbociclib)

Snippet

Sponsor: Olema Pharmaceuticals, Inc. | Conditions: Breast Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING